Abstract
I-123 IBF is a dopaminergic antagonist which is suitable for SPECT imaging of D2 receptors. The purpose of this study is to evaluate the potential usefulness of semi-quantitative parameters obtained from brain SPECT data of I-123 IBF for differential diagnosis in patients with parkinsonism (PN). Subjects were 10 patients with PN: 2 patients with striato-nigral degeneration (SND), 5 patients with Parkinson’s disease (PD), 2 patients with progressive supranuclear palsy (PSP) and one patient with olivo-ponto-cerebellar atrophy (OPCA). The data were acquired with a triple-head gamma camera at 2 hours after intravenous injection of 167 MBq of I-123 IBF. Transverse images were reconstructed by means of filtered backprojection, and attenuation correction was performed by Chang’s method (μ = 0.08). The basal ganglia-to-frontal cortex ratio (GFR) and the basal ganglia-to-occipital cortex ratio(GOR) on slices of 5 different thicknesses were calculated. The GFR and GOR were lower in the SND group than in the other disease groups in all slices with different thicknesses (7.2 mm, 14.4 mm, 21.6 mm, 28.8 mm and 43.2 mm). The semiquantitative parameters (GFR and GOR) obtained from brain SPECT data at 2 hours after intravenous injection of I-123 IBF may be useful for differential diagnosis in patients with PN.
This is a preview of subscription content, log in via an institution to check access.
References
Kung HF, Pan S, Kung MP, Billings J, Kasliwal R, Reilly J, et al.In vitro andin vivo evaluation of [123I]IBZM: A potential CNS D-2 dopamine receptor imaging agent.J Nucl Med 30: 88–92, 1989.
Tatsch K, Schwarz J, Oertel WH, Kirsh CM. SPECT imaging of dopamine D2 receptors with123I-IBZM: Initial experience in controls and patients with Pakinson’s syndrome and Wilson’s disease.Nucl Med Commun 12: 699–707, 1991.
Laulumaa V, Kuikka JT, Soininen H, Bergström K, Länsimies E, Riekkinen P. Imaging of D2 dopamine receptors of patients with Parkinson’s disease using single photon emission computed tomography and iodobenzamide I 123.Arch Neurol 50: 509–512, 1993.
Ichise M, Toyama H, Fornazzari L, Ballinger JR, Kirsh JC. Iodine-123-IBZM dopamine D2 receptor and technetium-99m-HMPAO brain perfusion SPECT in the evaluation of patients with and subjects at risk for Huntington’s disease.J Nucl Med 34: 1274–1281, 1993.
van Royen E, Verhoeff NF, Speelman JD, Wolters EC, Kuiper MA, Janssen AG. Multiple system atrophy and progressive supranuclear palsy. Diminished striatal D2 dopamine receptor activity demonstrated by123I-IBZM single photon emission computed tomography.Arch Neurol 50: 513–516, 1993.
Brücke T, Podreka I, Angelberger P, Wenger S, Topitz A, Kiifferle B, et al. Dopamine D2 receptor imaging with SPECT: Studies in different neuropsychiatric disorders.J Cereb Blood Flow Metab 11: 220–228, 1991.
Pilowsky LS, Costa DC, Ell PJ, Verhoeff NP, Murra RM, Kerwin RW. D2 dopamine receptor binding in the basal ganglia of antipsychotic-free shizophrenic patients. An123I-IBZM single photon emission computerised tomography study.Br J Psychiatry 164: 16–26, 1994.
Kung MP, Kung HF, Billings J, Yang Y, Murphy RA, Alavi A. The characterization of IBF as a new selective dopamine D-2 receptor imaging agent.J Nucl Med 31: 648–654, 1990.
Mozley PD, Stubbs JB, Kung HF, Selikson MH, Stabine MG, Alavi A. Biodistribution and dosimetry of Iodine-123-IBF: A potent radioligand for imaging the D2 dopamine receptor.J Nucl Med 34: 1910–1917, 1993.
Al-Tikriti MS, Baldwin RM, Zea-ponce Y, Sybirska E, Zoghbi SS, Lamelle M, et al. Comparison of three high affinity SPECT radiotracers for the dopamine D2 receptor.Nucl Med Biol 21: 179–188, 1994.
Lamelle M, van Dyck C, Abi-Dargham A, Zea-Ponce Y, Zoghbi SS, Charney DS, et al. Comparmental modeling of iodine-123-iodobenzofuran binding to dopamine D2 receptors in healthy subjects.J Nucl Med 35: 743–754, 1994.
Ichise M, Ballinger JR, Golan H, Vines D, Luong A, Tsai S, et al. Noninvasive quantification of dopamine D2 receptor with Iodine-123-IBF SPECT.J Nucl Med 37: 513–520, 1996.
Ichise M, Ballinger JR, Vines D, Tsai S, Kung HF. Simplified quantification and reproducibility studies of dopamine D2-receptor binding with Iodine-123-IBF SPECT in healthy subjects.J Nucl Med 38: 31–37, 1997.
Ichise M, Ballinger JR, Tanaka F, Moscovitch M, St Geroge-Hyslop PH, Raphael D. Age-related changes in D2 receptor binding with iodine-123-iodobenzofuran SPECT.J Nucl Med 39: 1511–1518, 1998.
Buck A, Westera G, Sutter M, Albani C, Kung HF, von Schulthess GK. Iodine-123-IBF SPECT evaluation of extrapyramidal diseases.J Nucl Med 36: 1196–1200, 1995.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Nakabeppu, Y., Nakajo, M., Mitsuda, M. et al. Iodine-123 iodobenzofuran (I-123 IBF) SPECT in patients with parkinsonism. Ann Nucl Med 13, 447–452 (1999). https://doi.org/10.1007/BF03164943
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF03164943